Longeveron (LGVN) Other Non-Current Assets (2021 - 2026)
Longeveron's (LGVN) quarterly Other Non-Current Assets came in at $18000.0 in Q1 2026, down 91.04% year-on-year from $201000.0 in Q1 2025, and down 89.77% quarter-over-quarter from $176000.0 in Q4 2025.
Longeveron (LGVN) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Longeveron's Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $18000.0 for Q1 2026.
- On a quarterly basis, Other Non-Current Assets fell 91.04% year-over-year to $18000.0 in Q1 2026; TTM through Mar 2026 was $18000.0, a 91.04% decrease from a year earlier, with the FY2025 full-year figure at $176000.0, down 12.87% from the prior year.
- Other Non-Current Assets declined to $18000.0 in Q1 2026 per LGVN's latest filing, from $176000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $247000.0 in Q1 2023 and bottomed at $18000.0 in Q1 2026.
- The 5-year median for Other Non-Current Assets is $200500.0 (2025), against an average of $191142.9.
- Across the five-year window, Other Non-Current Assets soared 37.85% in 2022 and tumbled 91.04% in 2026, its largest moves.
- Year by year, Other Non-Current Assets stood at $244000.0 in 2022, then fell by 20.9% to $193000.0 in 2023, then rose by 4.66% to $202000.0 in 2024, then fell by 12.87% to $176000.0 in 2025, then tumbled by 89.77% to $18000.0 in 2026.
- Per Business Quant, the three latest LGVN Other Non-Current Assets figures stand at $18000.0 (Q1 2026), $176000.0 (Q4 2025), and $178000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | 18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | 176,000.00 |
| Sep 30, 2025 | 178,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 201,000.00 |
| Dec 31, 2024 | 202,000.00 |
| Sep 30, 2024 | 203,000.00 |
| Jun 30, 2024 | 204,000.00 |
| Mar 31, 2024 | 190,000.00 |
| Dec 31, 2023 | 193,000.00 |
| Sep 30, 2023 | 197,000.00 |
| Jun 30, 2023 | 223,000.00 |
| Mar 31, 2023 | 247,000.00 |
| Dec 31, 2022 | 244,000.00 |
| Dec 31, 2021 | 177,000.00 |